Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $16,900 - $9.99 Million
-130,000 Reduced 58.86%
90,852 $6.46 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $3.27 Million - $3.6 Million
-45,000 Reduced 16.93%
220,852 $17 Million
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $3.69 Million - $4.42 Million
-60,000 Reduced 18.41%
265,852 $19.4 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $804,450 - $937,800
15,000 Added 4.83%
325,852 $20.3 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $7.99 Million - $9.36 Million
-135,000 Reduced 30.28%
310,852 $18.4 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $8.36 Million - $9.1 Million
135,000 Added 43.43%
445,852 $29.8 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $548,200 - $640,900
-10,000 Reduced 3.12%
310,852 $18.3 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $928,000 - $1.35 Million
-20,000 Reduced 5.87%
320,852 $17.9 Million
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $16.8 Million - $21.9 Million
340,852 New
340,852 $21.9 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $25.5 Million - $28.2 Million
-571,755 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $9.48 Million - $11.3 Million
210,000 Added 58.05%
571,755 $27.3 Million
Q4 2018

Feb 13, 2019

BUY
$48.76 - $63.23 $3.19 Million - $4.13 Million
65,367 Added 22.05%
361,755 $18.8 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $1.93 Million - $2.18 Million
-35,000 Reduced 10.56%
296,388 $18.4 Million
Q2 2018

Aug 10, 2018

BUY
$50.53 - $62.98 $1.52 Million - $1.89 Million
30,000 Added 9.95%
331,388 $18.3 Million
Q1 2018

May 14, 2018

BUY
$59.92 - $68.98 $1.8 Million - $2.07 Million
30,000 Added 11.05%
301,388 $19.1 Million
Q2 2017

Aug 14, 2017

BUY
N/A
271,388
271,388 $15.1 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Chescapmanager LLC Portfolio

Follow Chescapmanager LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chescapmanager LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chescapmanager LLC with notifications on news.